BioNTech: Advancing science to help transform cancer and ...
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases.
BioNTech - Wikipedia
BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz …
Welcome to our investor page | BioNTech
Dec 9, 2025 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious …
2026: A year of reckoning for BioNTech - European ...
6 days ago · For BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, …
JPM26: BioNTech gears up for multiproduct oncology status by …
4 days ago · Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.
BioNTech Provides Strategic Business Update and Outlines 2026 ...
6 days ago · 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and …
BioNTech Anticipates Landmark Year in Oncology with Robust ...
6 days ago · BioNTech SE anticipates a significant year in 2026, marked by advancements in its late-stage oncology pipeline, including plans for 15 Phase 3 clinical trials and seven data …